The ESC Textbook of Thrombosis

The ESC Textbook of Thrombosis is the third iteration of Therapeutic Advances in Thrombosis. Now a new addition to the European Society of Cardiology (ESC) publications portfolio, it is informed by the work of the ESC's Working Group on Thrombosis. Written by internationally renowned experts in the field of thrombosis, the textbook presents an up-to-date and in-depth review of all aspects of thrombosis and antithrombotic therapies. Not only does it reflect contemporary European guidelines from the ESC but also it also summarizes the latest evidence from clinical trials. Covering the topic in great detail with thirty-one chapters, the textbook is split into four sections: Pathophysiology of thrombosis, Clinical pharmacology of antithrombotic drugs, Therapeutic strategies, and Special situations. Appealing to the large community of cardiovascular healthcare specialists in Europe and across the world, the textbook is a must read for cardiologists dealing with acute and chronic coronary syndromes, atrial fibrillation, artificial heart valves and pulmonary embolism. It will also appeal to cardiac surgeons, cardiovascular researchers, and general physicians alike.

1 - Introduction
2 - Arterial thrombosis: Pathophysiological background
3 - Venous thrombosis and thromboembolism: Pathophysiological background
4 - Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background
5 - Thrombosis on foreign surfaces and devices
6 - Aspirin
7 - Platelet P2Y12 inhibitors
8 - Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists
9 - Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid
10 - Vitamin K antagonists
11 - Dabigatran
12 - Oral factor Xa (FXa) inhibitors
13 - Forthcoming oral factor XIa and FXIIa inhibitors
14 - Thrombolytic therapy and ancillary antithrombotic therapies
15 - Antithrombotic strategies in primary cardiovascular prevention
16 - Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions
17 - Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes
18 - Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions
19 - Antithrombotic therapies in ischaemic stroke
20 - Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis
21 - Atrial fibrillation: current and forthcoming antithrombotic therapies
22 - Venous thromboembolism: prophylaxis and treatment
23 - Biomarker-based risk stratification in cardiovascular disease
24 - Antithrombotic therapies in inherited or acquired thrombophilia
25 - Prevention and treatment of bleeding related to antithrombotic drug treatment
26 - Management of patients treated with antithrombotic drugs undergoing surgery
27 - Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome
28 - Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy
29 - Antithrombotic agents and drug-drug interactions
30 - Personalised antithrombotic therapy: Measuring individual variation and monitoring
31 - Drug development, clinical trials, and regulatory requirements

Raffaele De Caterina is Professor of Cardiology at the University of Pisa, and Director, University Cardiology Division, at Pisa University Hospital. He is also Scientific Advisor for the "G. Monasterio" Foundation, Pisa, Italy. He has been Vice-President of the European Society of Cardiology (2008-2010) and President (2009-2013) of the International Society on Nutrigenetics/Nutrigenomics. He is the past-Editor-in-Chief of the journal Vascular Pharmacology, curent Executive Editor of European Heart Journal, and author of >600 peer-reviewed manuscripts. Major research interests: Cardiovascular Pharmacology, Atrial Fibrillation, Coronary Artery Disease, Cardiovascular Thrombosis, Nutrigenetics and Nutrigenomics. David J. Moliterno, MD (FESC, FACC, FSCAI, FAHA) is a Professor at the University of Kentucky. He was an attending cardiologist at the Cleveland Clinic for 10 years before joining the University of Kentucky, where he was chief of cardiovascular medicine and subsequently chair of internal medicine. Dr. Moliterno has been a visiting professor or lecturer in more than 30 countries. He is the author of over 400 publications and editor of 8 textbooks. He has been the primary author of publications in BMJ, Circulation, EHJ, JACC, JAMA, Lancet, and NEJM. He is currently the Editor-in-Chief for the JACC: Cardiovascular Interventions and serves on the advisory board of the US FDA. As a clinical researcher, Dr. Moliterno has been a leader in numerous multinational investigational studies. Collectively, these studies have involved over $1 billion in clinical trial research. His primary interests involve acute coronary syndromes, antithrombotic therapies, and interventional cardiology. Steen Dalby Kristensen is a professor and interventional cardiologist at Aarhus University Hospital, Denmark. Scientific/clinical interests: Thrombosis and anti-thrombotic treatment. Coronary artery disease and acute cardiac care. Percutaneous coronary interventions. Author of more than 365 scientific papers and 17 book chapters. Editor of 5 textbooks. Editor of European Heart Journal, Thrombosis and Haemostasis and European Heart Journal: Acute Cardiovascular Care. Invited speaker in more than 40 different countries. Supervisor of 15 PhD students. Chair of international research committees for evaluation of scientific applications in Germany and Spain. Evaluator of grants in Sweden, Norway, Italy, Germany, Spain, Finland and Denmark. Has been ESC Vice-president, ESC secretary/treasurer and leader of several key ESC initiatives, ESC committees and working groups. Past President of the Danish Society of Cardiology